<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409731</url>
  </required_header>
  <id_info>
    <org_study_id>16-310</org_study_id>
    <nct_id>NCT03409731</nct_id>
  </id_info>
  <brief_title>Absorb GT1 Japan PMS</brief_title>
  <official_title>Absorb GT1 Bioresorbable Vascular Scaffold (BVS) System Post-marketing Surveillance (PMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Surveillance is to know the frequency and status of adverse device effects&#xD;
      and adverse events in order to assure the safety of the new medical device, and to collect&#xD;
      efficacy and safety information for evaluating clinical use results.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The surveillance consists of two phases as detailed below. All patients will be continuously&#xD;
      registered in each phases.&#xD;
&#xD;
      Phase 1 (All- patients): Includes 250 patients (approximately 45 sites)&#xD;
&#xD;
      Main Purpose: To confirm the efficacy of physician training and to establish optimal training&#xD;
      for increasing medical institutions participating in post-marketing evaluation. Procedural&#xD;
      results will be evaluated sequentially for early feedback to the sites. Therefore, there will&#xD;
      be no quantitative goal established to move to Phase 2. However, recommended procedure may be&#xD;
      updated as required in order to achieve optimal acute result.&#xD;
&#xD;
      Phase 2 (All- patients): Until 2000 patients are registered (up to 200 sites) Main Purpose:&#xD;
      To confirm safety.&#xD;
&#xD;
      Target sample size of the Surveillance is approximately 2,000 patients. Commercial sale of&#xD;
      Absorb GT1 beyond the purpose of the Surveillance will be started if the scaffold thrombosis&#xD;
      (ST) rate in the 2,000 patients at 3 month is 0.9% or lower (ST rates for patients with&#xD;
      Absorb GT1).&#xD;
&#xD;
      In the ABSORB III (NCT01751906) clinical trial, 19 events of definite/probable ST reported&#xD;
      through 1 year, and 18 of them except 1 occurred within 3 months (maximum of 78 days)&#xD;
      post-procedure. Therefore, it is appropriate to perform interim analysis for the safety using&#xD;
      ST rate through 3 months. The event occurred after 3 months was reported 362 days after the&#xD;
      procedure, and the patient stopped treatment with thienopyridine antiplatelet agent on Day&#xD;
      356.&#xD;
&#xD;
      Both in the AVJ-301 (NCT01844284) and the ABSORB III clinical trials, ST rate through 1 year&#xD;
      was 1.5%. In the ABSORB III clinical trial, ST rate in target lesion with Reference Vessel&#xD;
      Diameter (RVD) ≥ 2.25 mm was 0.9%. As explained above, ST rates at 3 months and 1 year are&#xD;
      almost similar. The half widths of the 95% confidence intervals (CI) to different sample&#xD;
      sizes are presented in the table 2.3-1. The half width of 95% CI decreases from 0.6% to 0.4%&#xD;
      when a sample size is increased from 1,000 to 2,000. However, further increase in the sample&#xD;
      size does not result in significant decrease in the half width of 95% CI. Therefore, the&#xD;
      sample size of the Surveillance was established as 2,000 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 13, 2016</start_date>
  <completion_date type="Anticipated">January 15, 2023</completion_date>
  <primary_completion_date type="Actual">May 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Acute Scaffold Thrombosis (ST)</measure>
    <time_frame>Day 0</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Sub Acute Scaffold Thrombosis (ST)</measure>
    <time_frame>&gt;1 to 30 days</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Late Scaffold Thrombosis (ST)</measure>
    <time_frame>31 to 90 days</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Late Scaffold Thrombosis (ST)</measure>
    <time_frame>31 to 365 days</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Very Late Scaffold Thrombosis (ST)</measure>
    <time_frame>366 to 730 days</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Overall Scaffold Thrombosis (ST)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Cumulative Scaffold Thrombosis</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Cumulative Scaffold Thrombosis</measure>
    <time_frame>0 to 730 days</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Exclusion of Very Small Vessels</measure>
    <time_frame>During index procedure, &quot;54.8 ± 27.6 min&quot;</time_frame>
    <description>For Phase 1 patients, Angiograms and IVUS/OCT images taken during procedure will be sent immediately to the core lab. Additional training or revision of registration criteria may occur as required in order to exclude almost all lesions with RVD &lt; 2.5 mm from registration by the last half of Phase 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Scaffold Apposition Assessed by Intravascular Imaging</measure>
    <time_frame>During index procedure, &quot;54.8 ± 27.6 min&quot;</time_frame>
    <description>IVUS/OCT images taken during procedure will be sent immediately to the core lab, which will analyze the images and give feedback to the site as required. Images of ST, if occurred, will also be sent to the core lab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Composite of Device Deficiencies</measure>
    <time_frame>During index procedure, &quot;54.8 ± 27.6 min&quot;</time_frame>
    <description>Device deficiencies: Number of participants with at least one of the following Device deficiencies&#xD;
Lesion/implant failure&#xD;
Delivery difficulty (finally delivered)&#xD;
Re-crossing failure&#xD;
Re-crossing difficulty&#xD;
Post-dilatation balloon&#xD;
Optical Coherence Tomography (OCT)/Intravascular Ultrasound (IVUS)&#xD;
Instruction for Use (IFU) not included&#xD;
Major Strut Malapposition&#xD;
Strut Fracture within 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death/MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death/MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death/MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death/MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 1 Year</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis): Lesion Morphology</measure>
    <time_frame>Pre-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis):Thrombolysis in Myocardial Infarction (TIMI) Blood Flow</measure>
    <time_frame>Pre-procedure</time_frame>
    <description>TIMI 0 flow (no perfusion) refers to the absence of any antegrade flow beyond a coronary occlusion.&#xD;
TIMI 1 flow (penetration without perfusion) is faint antegrade coronary flow beyond the occlusion, with incomplete filling of the distal coronary bed.&#xD;
TIMI 2 flow (partial reperfusion) is delayed or sluggish antegrade flow with complete filling of the distal territory.&#xD;
TIMI 3 is normal flow which fills the distal coronary bed completely</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis): Lesion Length</measure>
    <time_frame>Pre-procedure</time_frame>
    <description>Lesion Length (can be measured after successful post-dilatation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis): Proximal Reference Vessel Diameter (RVD)</measure>
    <time_frame>Pre-procedure</time_frame>
    <description>Proximal RVD (can be measured after successful post-dilatation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis): Distal RVD</measure>
    <time_frame>Pre-procedure</time_frame>
    <description>Distal RVD (can be measured after successful post-dilatation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis): Minimum Lumen Diameter (MLD)</measure>
    <time_frame>Pre-procedure</time_frame>
    <description>Angiographic endpoint Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis): Percent Diameter Stenosis (%DS)</measure>
    <time_frame>Pre-procedure</time_frame>
    <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis): Thrombolysis in Myocardial Infarction (TIMI) Blood Flow</measure>
    <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
    <description>TIMI 0 flow (no perfusion) refers to the absence of any antegrade flow beyond a coronary occlusion.&#xD;
TIMI 1 flow (penetration without perfusion) is faint antegrade coronary flow beyond the occlusion, with incomplete filling of the distal coronary bed.&#xD;
TIMI 2 flow (partial reperfusion) is delayed or sluggish antegrade flow with complete filling of the distal territory.&#xD;
TIMI 3 is normal flow which fills the distal coronary bed completely</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis): MLD (In-segment)</measure>
    <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
    <description>Angiographic endpoint. Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.&#xD;
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis): %DS (In-Segment )</measure>
    <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
    <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA). In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Endpoints (Core Lab Analysis): Acute Gain (In-Segment )</measure>
    <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
    <description>The acute gain was defined as the difference between post- and pre procedural minimal lumen diameter (MLD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS/OCT Endpoints (Core Lab Analysis): Lumen Diameter or Lumen Area (Proximal/Distal)</measure>
    <time_frame>Pre-procedure (or after pre-dilatation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS/OCT Endpoints (Core Lab Analysis): Lumen Diameter or Lumen Area (Proximal/Distal)</measure>
    <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS/OCT Endpoints (Core Lab Analysis): Minimal Lumen Area</measure>
    <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS/OCT Endpoints (Core Lab Analysis): Percentage of Lesions With Strut Malapposition</measure>
    <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
    <description>Percentage of lesions with strut malapposition will be calculated as mean ± standard deviation post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS/OCT Endpoints (Core Lab Analysis): Percentage of Strut Fracture</measure>
    <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
    <description>Strut fracture will be measured as either number or percentage post-procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Angina Pectoris</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Occlusion</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Absorb GT1 BVS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ABSORB GT1 BVS</intervention_name>
    <description>Patients receiving Absorb GT1 BVS</description>
    <arm_group_label>Absorb GT1 BVS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General Percutaneous coronary intervention (PCI) population.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No specific exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masato Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toho University Ohashi Medical Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya Daini Red Cross Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Tokyo Hospital</name>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <zip>270-2232</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Koga Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanaoka Seishu Memorial Cardiovascular Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>062-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Sekishinkai Hospital</name>
      <address>
        <city>Sayama</city>
        <state>Saitama</state>
        <zip>350-1323</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitsui Memorial Museum</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <zip>101-8643</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Kumamoto Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-4193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Medical Association Hospital</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <results_first_submitted>December 7, 2018</results_first_submitted>
  <results_first_submitted_qc>December 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2019</results_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting Bio-resolvable Scaffold (BRS)</keyword>
  <keyword>Bio-resolvable Scaffold (BRS)</keyword>
  <keyword>Real world</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03409731/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03409731/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This Post-marketing Surveillance study was conducted in patients with ischemic heart disease potentially indicated for treatment with the Absorb GT1 Bioresorbable Vascular Scaffold System. A total of 135 patients were enrolled between December 13, 2016 to December 11, 2017 time period.</recruitment_details>
      <pre_assignment_details>The proposed target sample size of the surveillance was approximately 2,000 patients. However, only 135 patients were registered in this study since Absorb GT1 was withdrawn from global market, due to low sales volume.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Absorb GT1 BVS</title>
          <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Absorb GT1 BVS</title>
          <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dyslipidemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal Failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Coronary Intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Myocardial Infarction (MI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Scaffold Thrombosis (ST)</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>Day 0</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Scaffold Thrombosis (ST)</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sub Acute Scaffold Thrombosis (ST)</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>&gt;1 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sub Acute Scaffold Thrombosis (ST)</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Late Scaffold Thrombosis (ST)</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>31 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Late Scaffold Thrombosis (ST)</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Late Scaffold Thrombosis (ST)</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>31 to 365 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Late Scaffold Thrombosis (ST)</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Very Late Scaffold Thrombosis (ST)</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>366 to 730 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Very Late Scaffold Thrombosis (ST)</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Overall Scaffold Thrombosis (ST)</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Scaffold Thrombosis (ST)</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cumulative Scaffold Thrombosis</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Scaffold Thrombosis</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cumulative Scaffold Thrombosis</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>0 to 730 days</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Scaffold Thrombosis</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).&#xD;
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.&#xD;
Timings:&#xD;
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Exclusion of Very Small Vessels</title>
        <description>For Phase 1 patients, Angiograms and IVUS/OCT images taken during procedure will be sent immediately to the core lab. Additional training or revision of registration criteria may occur as required in order to exclude almost all lesions with RVD &lt; 2.5 mm from registration by the last half of Phase 1.</description>
        <time_frame>During index procedure, &quot;54.8 ± 27.6 min&quot;</time_frame>
        <population>Full Analysis Set (phase 1 participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Exclusion of Very Small Vessels</title>
          <description>For Phase 1 patients, Angiograms and IVUS/OCT images taken during procedure will be sent immediately to the core lab. Additional training or revision of registration criteria may occur as required in order to exclude almost all lesions with RVD &lt; 2.5 mm from registration by the last half of Phase 1.</description>
          <population>Full Analysis Set (phase 1 participants with Absorb GT1)</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 2.25 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2.25 mm - &lt; 2.5 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2.5 mm - ≤ 3.5 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 3.5 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Scaffold Apposition Assessed by Intravascular Imaging</title>
        <description>IVUS/OCT images taken during procedure will be sent immediately to the core lab, which will analyze the images and give feedback to the site as required. Images of ST, if occurred, will also be sent to the core lab.</description>
        <time_frame>During index procedure, &quot;54.8 ± 27.6 min&quot;</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Scaffold Apposition Assessed by Intravascular Imaging</title>
          <description>IVUS/OCT images taken during procedure will be sent immediately to the core lab, which will analyze the images and give feedback to the site as required. Images of ST, if occurred, will also be sent to the core lab.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite of Device Deficiencies</title>
        <description>Device deficiencies: Number of participants with at least one of the following Device deficiencies&#xD;
Lesion/implant failure&#xD;
Delivery difficulty (finally delivered)&#xD;
Re-crossing failure&#xD;
Re-crossing difficulty&#xD;
Post-dilatation balloon&#xD;
Optical Coherence Tomography (OCT)/Intravascular Ultrasound (IVUS)&#xD;
Instruction for Use (IFU) not included&#xD;
Major Strut Malapposition&#xD;
Strut Fracture within 6 months</description>
        <time_frame>During index procedure, &quot;54.8 ± 27.6 min&quot;</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Device Deficiencies</title>
          <description>Device deficiencies: Number of participants with at least one of the following Device deficiencies&#xD;
Lesion/implant failure&#xD;
Delivery difficulty (finally delivered)&#xD;
Re-crossing failure&#xD;
Re-crossing difficulty&#xD;
Post-dilatation balloon&#xD;
Optical Coherence Tomography (OCT)/Intravascular Ultrasound (IVUS)&#xD;
Instruction for Use (IFU) not included&#xD;
Major Strut Malapposition&#xD;
Strut Fracture within 6 months</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lesion/implant failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delivery difficulty (finally delivered)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Re-crossing failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Re-crossing difficulty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dilatation balloon+OCT/IVUS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFU not included</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Strut Malapposition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strut Fracture within 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
        <time_frame>0 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.&#xD;
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
        <time_frame>0 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>All coronary revascularization is a composite of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death/MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death/MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death/MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death/MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death/MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death/MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death/MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>0 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death/MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR)</description>
        <time_frame>0 to 1 Year</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR)</description>
        <time_frame>0 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR)</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Major Adverse Cardiac Event (MACE)</title>
        <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Major Adverse Cardiac Event (MACE)</title>
          <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Major Adverse Cardiac Event (MACE)</title>
        <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Major Adverse Cardiac Event (MACE)</title>
          <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Major Adverse Cardiac Event (MACE)</title>
        <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Major Adverse Cardiac Event (MACE)</title>
          <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Major Adverse Cardiac Event (MACE)</title>
        <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
        <time_frame>0 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Major Adverse Cardiac Event (MACE)</title>
          <description>MACE is the composite of Cardiac death/All myocardial infarction (MI)/ Ischemia-driven Revascularization (ID-TLR)</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death/Myocardial Infarction (MI)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis): Lesion Morphology</title>
        <time_frame>Pre-procedure</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis): Lesion Morphology</title>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACC/AHA Type B2/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe/Moderate Calcification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eccentric</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis):Thrombolysis in Myocardial Infarction (TIMI) Blood Flow</title>
        <description>TIMI 0 flow (no perfusion) refers to the absence of any antegrade flow beyond a coronary occlusion.&#xD;
TIMI 1 flow (penetration without perfusion) is faint antegrade coronary flow beyond the occlusion, with incomplete filling of the distal coronary bed.&#xD;
TIMI 2 flow (partial reperfusion) is delayed or sluggish antegrade flow with complete filling of the distal territory.&#xD;
TIMI 3 is normal flow which fills the distal coronary bed completely</description>
        <time_frame>Pre-procedure</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis):Thrombolysis in Myocardial Infarction (TIMI) Blood Flow</title>
          <description>TIMI 0 flow (no perfusion) refers to the absence of any antegrade flow beyond a coronary occlusion.&#xD;
TIMI 1 flow (penetration without perfusion) is faint antegrade coronary flow beyond the occlusion, with incomplete filling of the distal coronary bed.&#xD;
TIMI 2 flow (partial reperfusion) is delayed or sluggish antegrade flow with complete filling of the distal territory.&#xD;
TIMI 3 is normal flow which fills the distal coronary bed completely</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>percentage of TIMI flow</units>
          <param>Number</param>
          <units_analyzed>Lesion</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesion</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis): Lesion Length</title>
        <description>Lesion Length (can be measured after successful post-dilatation)</description>
        <time_frame>Pre-procedure</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis): Lesion Length</title>
          <description>Lesion Length (can be measured after successful post-dilatation)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.84" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis): Proximal Reference Vessel Diameter (RVD)</title>
        <description>Proximal RVD (can be measured after successful post-dilatation)</description>
        <time_frame>Pre-procedure</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis): Proximal Reference Vessel Diameter (RVD)</title>
          <description>Proximal RVD (can be measured after successful post-dilatation)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis): Distal RVD</title>
        <description>Distal RVD (can be measured after successful post-dilatation)</description>
        <time_frame>Pre-procedure</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis): Distal RVD</title>
          <description>Distal RVD (can be measured after successful post-dilatation)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis): Minimum Lumen Diameter (MLD)</title>
        <description>Angiographic endpoint Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen</description>
        <time_frame>Pre-procedure</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis): Minimum Lumen Diameter (MLD)</title>
          <description>Angiographic endpoint Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis): Percent Diameter Stenosis (%DS)</title>
        <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
        <time_frame>Pre-procedure</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis): Percent Diameter Stenosis (%DS)</title>
          <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>percentage of diameter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis): Thrombolysis in Myocardial Infarction (TIMI) Blood Flow</title>
        <description>TIMI 0 flow (no perfusion) refers to the absence of any antegrade flow beyond a coronary occlusion.&#xD;
TIMI 1 flow (penetration without perfusion) is faint antegrade coronary flow beyond the occlusion, with incomplete filling of the distal coronary bed.&#xD;
TIMI 2 flow (partial reperfusion) is delayed or sluggish antegrade flow with complete filling of the distal territory.&#xD;
TIMI 3 is normal flow which fills the distal coronary bed completely</description>
        <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis): Thrombolysis in Myocardial Infarction (TIMI) Blood Flow</title>
          <description>TIMI 0 flow (no perfusion) refers to the absence of any antegrade flow beyond a coronary occlusion.&#xD;
TIMI 1 flow (penetration without perfusion) is faint antegrade coronary flow beyond the occlusion, with incomplete filling of the distal coronary bed.&#xD;
TIMI 2 flow (partial reperfusion) is delayed or sluggish antegrade flow with complete filling of the distal territory.&#xD;
TIMI 3 is normal flow which fills the distal coronary bed completely</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>percentage of TIMI flow</units>
          <param>Number</param>
          <units_analyzed>Lesion</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesion</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis): MLD (In-segment)</title>
        <description>Angiographic endpoint. Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.&#xD;
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
        <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis): MLD (In-segment)</title>
          <description>Angiographic endpoint. Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.&#xD;
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis): %DS (In-Segment )</title>
        <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA). In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
        <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis): %DS (In-Segment )</title>
          <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA). In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>percentage of diameter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Endpoints (Core Lab Analysis): Acute Gain (In-Segment )</title>
        <description>The acute gain was defined as the difference between post- and pre procedural minimal lumen diameter (MLD).</description>
        <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Endpoints (Core Lab Analysis): Acute Gain (In-Segment )</title>
          <description>The acute gain was defined as the difference between post- and pre procedural minimal lumen diameter (MLD).</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVUS/OCT Endpoints (Core Lab Analysis): Lumen Diameter or Lumen Area (Proximal/Distal)</title>
        <time_frame>Pre-procedure (or after pre-dilatation)</time_frame>
        <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>IVUS/OCT Endpoints (Core Lab Analysis): Lumen Diameter or Lumen Area (Proximal/Distal)</title>
          <population>The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.04" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.29" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVUS/OCT Endpoints (Core Lab Analysis): Lumen Diameter or Lumen Area (Proximal/Distal)</title>
        <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>IVUS/OCT Endpoints (Core Lab Analysis): Lumen Diameter or Lumen Area (Proximal/Distal)</title>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.21" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.54" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVUS/OCT Endpoints (Core Lab Analysis): Minimal Lumen Area</title>
        <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>IVUS/OCT Endpoints (Core Lab Analysis): Minimal Lumen Area</title>
          <population>Full Analysis Set (all participants with Absorb GT1).</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVUS/OCT Endpoints (Core Lab Analysis): Percentage of Lesions With Strut Malapposition</title>
        <description>Percentage of lesions with strut malapposition will be calculated as mean ± standard deviation post-procedure</description>
        <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>IVUS/OCT Endpoints (Core Lab Analysis): Percentage of Lesions With Strut Malapposition</title>
          <description>Percentage of lesions with strut malapposition will be calculated as mean ± standard deviation post-procedure</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Percentage of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVUS/OCT Endpoints (Core Lab Analysis): Percentage of Strut Fracture</title>
        <description>Strut fracture will be measured as either number or percentage post-procedure</description>
        <time_frame>Post-procedure (average procedure time of &quot;54.8 ± 27.6 min&quot;)</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>IVUS/OCT Endpoints (Core Lab Analysis): Percentage of Strut Fracture</title>
          <description>Strut fracture will be measured as either number or percentage post-procedure</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Lesions</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Absorb GT1 BVS</title>
          <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL INFARCTION/ACS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>PAROXYSMAL ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>STABLE ANGINA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>STABLE CORONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE INTESTINAL INFRAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH UNKNOWN CAUSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CHOLESYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>GALLSTONE ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA B VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>INFLUENZA VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>LUNG CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>TRAUMATIC SUBARACHNOID HEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CANCER OF HEAD OF PANCREAS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIOGENIC CEREBRAL OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>INTERNAL CAROTID ARTERY OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>INTERNAL CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>SECONDARY HYDROCEPHALIC CONDITION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>PROSTATIC HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>STABLE CORONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>STENT THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BILATERAL MIDDLE CEREBRAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 11.0">DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 11.0">TLR</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hajime Kusano</name_or_title>
      <organization>Abbott medical device</organization>
      <phone>+1 408-845-1626</phone>
      <email>hajime.kusano@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

